| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39155 | GLAXOSMITHKLINE | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jul, 2013
(10 years ago) | |
|
USRE39155 (Pediatric) | GLAXOSMITHKLINE | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jan, 2014
(10 years ago) | |
| US5905082 | GLAXOSMITHKLINE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | GLAXOSMITHKLINE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6004968 | GLAXOSMITHKLINE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(6 years ago) | |
|
US6004968 (Pediatric) | GLAXOSMITHKLINE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(5 years ago) | |
Epivir-Hbv is owned by Glaxosmithkline.
Epivir-Hbv contains Lamivudine.
Epivir-Hbv has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Epivir-Hbv are:
- USRE39155
- USRE39155*PED
- US5905082
- US5905082*PED
- US6004968
- US6004968*PED
Epivir-Hbv was authorised for market use on 08 December, 1998.
Epivir-Hbv is available in tablet;oral, solution;oral dosage forms.
Epivir-Hbv can be used as treatment of hepatitis b infection.
The generics of Epivir-Hbv are possible to be released after 20 September, 2018.
Drugs and Companies using LAMIVUDINE ingredient
Market Authorisation Date: 08 December, 1998
Treatment: Treatment of hepatitis b infection
Dosage: TABLET;ORAL; SOLUTION;ORAL
EPIVIR-HBV family patents
